Advertisement

Annals of Surgical Oncology

, Volume 22, Issue 7, pp 2253–2261 | Cite as

Impact of Steatosis on Prognosis of Patients with Early-Stage Hepatocellular Carcinoma After Hepatic Resection

  • Chien-Wei Su
  • Gar-Yang Chau
  • Hung-Hsu Hung
  • Yi-Chen Yeh
  • Hao-Jan Lei
  • Cheng-Yuan Hsia
  • Chiung-Ru Lai
  • Han-Chieh Lin
  • Jaw-Ching Wu
Hepatobiliary Tumors

Abstract

Background

It is still unclear whether steatosis determines the prognosis of patients with hepatocellular carcinoma (HCC). This study aimed to compare the clinical manifestations and outcomes between early-stage HCC patients with and without steatosis after hepatic resection.

Methods

We enrolled 188 patients who underwent hepatic resection for HCC within the Milan criteria. After surgery, fibrosis, steatosis, lobular inflammation, portal inflammation, and ballooning in the background liver were assessed. Factors related to prognosis after surgery were analyzed by multivariate analysis.

Results

Seventy-four patients (39.4 %) had steatosis. Patients with steatosis had larger body mass index, higher fasting glucose levels, and higher rates of ballooning than those without steatosis. After a median follow-up period of 69.8 months, 73 patients died. The cumulative survival rates at 5 years were 57.8 and 75.6 % for patients with and without steatosis, respectively (p = 0.008). Multivariate analysis disclosed that an age of > 65 years [hazard ratio (HR) 1.996, p = 0.009], platelet count of <105/mm3 (HR 2.198, p = 0.005), indocyanine green retention rate at 15 min of >10 % (HR 2.037, p = 0.022), multinodularity (HR 2.389, p = 0.004), and steatosis (HR 1.773, p = 0.023) were independent risk factors associated with poor overall survival after resection. The impact of steatosis on postsurgical prognosis was more apparent in patients without cirrhosis.

Conclusions

The presence of steatosis in the background liver was associated with a poor prognosis in early-stage HCC patients after hepatic resection, especially for noncirrhotic patients.

Keywords

Hepatic Resection Milan Criterion Background Liver Lobular Inflammation Portal Inflammation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgment

This work was supported by grants from the National Science Council of Taiwan (NSC 101-2314-B-075-013-MY2), Taipei Veterans General Hospital (V102C-117, C103C-055, VGHUST100-G7-2-1), Yang-Ming University (101AC-T501, Ministry of Education, Aim for the Top University Plan), and the Center of Excellence for Cancer Research at TVGH (DOH102-TD-C-111-007), Taipei, Taiwan.

Disclosure

The authors declare no conflict of interest.

Supplementary material

10434_2014_4221_MOESM1_ESM.docx (41 kb)
Supplementary material 1 (DOCX 41 kb)

References

  1. 1.
    de Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of HCC. J Hepatol. 2012;56(Suppl 1):S75–87.PubMedCrossRefGoogle Scholar
  2. 2.
    Su CW, Chiou YW, Tsai YH, et al. The influence of hepatitis B viral load and pre-S deletion mutations on post-operative recurrence of hepatocellular carcinoma and the tertiary preventive effects by anti-viral therapy. PLoS One. 2013;8:e66457.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol. 2012;56:1384–91.PubMedCrossRefGoogle Scholar
  4. 4.
    Welzel TM, Graubard BI, Quraishi S, et al. Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am J Gastroenterol. 2013;108:1314–21.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Wong VW, Wong GL, Choi PC, et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut. 2010;59:969–74.PubMedCrossRefGoogle Scholar
  6. 6.
    Armstrong MJ, Houlihan DD, Bentham L, et al. Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. J Hepatol. 2012;56:234–40.PubMedCrossRefGoogle Scholar
  7. 7.
    Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274–85.PubMedCrossRefGoogle Scholar
  8. 8.
    Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med. 2003;348:1625–38.PubMedCrossRefGoogle Scholar
  9. 9.
    Su CW, Lei HJ, Chau GY, et al. The effect of age on the long-term prognosis of patients with hepatocellular carcinoma after resection surgery: a propensity score matching analysis. Arch Surg. 2012;147:137–44.PubMedCrossRefGoogle Scholar
  10. 10.
    Fan ST, Mau Lo C, Poon RT, et al. Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: a 20-year experience. Ann Surg. 2011;253:745–58.PubMedCrossRefGoogle Scholar
  11. 11.
    Kim SH, Choi SB, Lee JG, et al. Prognostic factors and 10-year survival in patients with hepatocellular carcinoma after curative hepatectomy. J Gastrointest Surg. 2011;15:598–607.PubMedCrossRefGoogle Scholar
  12. 12.
    Santi V, Buccione D, Di Micoli A, et al. The changing scenario of hepatocellular carcinoma over the last two decades in Italy. J Hepatol. 2012;56:397–405.PubMedCrossRefGoogle Scholar
  13. 13.
    Wu TH, Yu MC, Chan KM, et al. Prognostic effect of steatosis on hepatocellular carcinoma patients after liver resection. Eur J Surg Oncol. 2011;37:618–22.PubMedCrossRefGoogle Scholar
  14. 14.
    Reddy SK, Steel JL, Chen HW, et al. Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. Hepatology. 2012;55:1809–19.PubMedCrossRefGoogle Scholar
  15. 15.
    Cauchy F, Zalinski S, Dokmak S, et al. Surgical treatment of hepatocellular carcinoma associated with the metabolic syndrome. Br J Surg. 2013;100:113–21.PubMedCrossRefGoogle Scholar
  16. 16.
    Wu CY, Chen YJ, Ho HJ, et al. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA. 2012;308:1906–14.PubMedCrossRefGoogle Scholar
  17. 17.
    Chan AC, Chok KS, Yuen WK, et al. Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus–related hepatocellular carcinoma. Arch Surg. 2011;146:675–81.PubMedCrossRefGoogle Scholar
  18. 18.
    Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467–74.PubMedCrossRefGoogle Scholar
  21. 21.
    Law K, Brunt EM. Nonalcoholic fatty liver disease. Clin Liver Dis. 2010;14:591–604.PubMedCrossRefGoogle Scholar
  22. 22.
    Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421–30.PubMedCrossRefGoogle Scholar
  23. 23.
    Wu WC, Wu CY, Wang YJ, et al. Updated thresholds for serum alanine aminotransferase level in a large-scale population study composed of 34346 subjects. Aliment Pharmacol Ther. 2012;36:560–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Stickel F, Hellerbrand C. Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications. Gut. 2010;59:1303–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Chen CL, Yang HI, Yang WS, et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology. 2008;135:111–21.PubMedCrossRefGoogle Scholar
  26. 26.
    Wu JC, Huang YH, Chau GY, et al. Risk factors for early and late recurrence in hepatitis B–related hepatocellular carcinoma. J Hepatol. 2009;51:890–7.PubMedCrossRefGoogle Scholar
  27. 27.
    Nault JC, De Reynies A, Villanueva A, et al. A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology. 2013;145:176–87.PubMedCrossRefGoogle Scholar
  28. 28.
    Hung HH, Chiou YY, Hsia CY, et al. Survival rates are comparable after radiofrequency ablation or surgery in patients with small hepatocellular carcinomas. Clin Gastroenterol Hepatol. 2011;9:79–86.PubMedCrossRefGoogle Scholar
  29. 29.
    Roayaie S, Obeidat K, Sposito C, et al. Resection of hepatocellular cancer ≤2 cm: results from two Western centers. Hepatology. 2013;57:1426–35.PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Hung HH, Su CW, Lai CR, et al. Fibrosis and AST to platelet ratio index predict post-operative prognosis for solitary small hepatitis B–related hepatocellular carcinoma. Hepatol Int. 2010;4:691–9.PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Wu WC, Chiou YY, Hung HH, et al. Prognostic significance of computed tomography scan–derived splenic volume in hepatocellular carcinoma treated with radiofrequency ablation. J Clin Gastroenterol. 2012;46:789–95.PubMedCrossRefGoogle Scholar
  32. 32.
    Sanyal AJ, Banas C, Sargeant C, et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology. 2006;43:682–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010;51:1972–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology. 2011;53:810–20.PubMedCentralPubMedCrossRefGoogle Scholar
  35. 35.
    Pais R, Charlotte F, Fedchuk L, et al. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol. 2013;59:550–6.PubMedCrossRefGoogle Scholar
  36. 36.
    Hashimoto E, Yatsuji S, Tobari M, et al. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Gastroenterol. 2009;44(Suppl 19):89–95.PubMedCrossRefGoogle Scholar
  37. 37.
    Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int. 2009;29:502–10.PubMedCentralPubMedCrossRefGoogle Scholar
  38. 38.
    Chen CH, Huang MH, Yang JC, et al. Prevalence and etiology of elevated serum alanine aminotransferase level in an adult population in Taiwan. J Gastroenterol Hepatol. 2007;22:1482–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–5.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2014

Authors and Affiliations

  • Chien-Wei Su
    • 1
    • 2
  • Gar-Yang Chau
    • 2
    • 3
  • Hung-Hsu Hung
    • 2
    • 4
    • 5
  • Yi-Chen Yeh
    • 2
    • 4
    • 6
  • Hao-Jan Lei
    • 2
    • 3
  • Cheng-Yuan Hsia
    • 2
    • 3
  • Chiung-Ru Lai
    • 2
    • 6
  • Han-Chieh Lin
    • 1
    • 2
  • Jaw-Ching Wu
    • 4
    • 7
  1. 1.Division of Gastroenterology, Department of MedicineTaipei Veterans General HospitalTaipeiTaiwan
  2. 2.Faculty of Medicine, School of MedicineNational Yang-Ming UniversityTaipeiTaiwan
  3. 3.Division of General Surgery, Department of SurgeryTaipei Veterans General HospitalTaipeiTaiwan
  4. 4.Institute of Clinical Medicine, School of Medicine and Cancer Research CenterNational Yang-Ming UniversityTaipeiTaiwan
  5. 5.Division of Gastroenterology, Department of MedicineCheng Hsin General HospitalTaipeiTaiwan
  6. 6.Department of Pathology and Laboratory MedicineTaipei Veterans General HospitalTaipeiTaiwan
  7. 7.Division of Translational Research, Department of Medical ResearchTaipei Veterans General HospitalTaipeiTaiwan

Personalised recommendations